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Respiratory diseases are common in children and 
carry a significant burden of morbidity and mortality 
in this age group worldwide.[1] Lower respiratory tract 
infections (LRTIs) are defined as infections that affect 
airways below the epiglottis. The term is often used as 
a synonym for pneumonia, which is defined as inflammation of the 
lung parenchyma with cough, dyspnoea and indrawing of the chest 
wall the most common presenting symptoms and signs.[2]
Healthy children are vulnerable to pneumonia when the immune 
system is weakened by factors such as immunosuppression, 
malnutrition, measles, overcrowded homes, parental smoking or 
indoor pollution. Several steps have been established by the World 
Health Organization (WHO) to reduce mortality and morbidity due 
to pneumonia. These include immunisation, promotion of adequate 
nutrition (including breastfeeding and zinc intake), reduction 
of indoor air pollution, and implementation of the Integrated 
Management of Childhood Illness (IMCI) programme.[3] Pneumonia 
currently accounts for 20% of deaths of children under 5 years of 
age in developing countries every year, and remains an important 
condition in HIV-infected children.[4]
An estimated 330 000 children acquired HIV infection in 2011, 
and more than 90% of these lived in sub-Saharan Africa.[5] In South 
Africa (SA), between 410 000 and 520 000 children aged 0 - 14 years 
are living with HIV.[6] Of the approximately 2.1 million children 
who are infected with HIV type 1, more than 80% will develop a 
respiratory illness at some stage during the course of their disease.[7]
The advent of highly active antiretroviral therapy (HAART) 
has changed the natural progression of the disease, reducing 
viral replication, increasing the number of CD4 lymphocytes, 
and thus re-establishing host defences and improving survival.[8] 
Nevertheless, even on HAART children remain more vulnerable 
to infections than their healthy uninfected peers.[9] A reduction in 
the rate of opportunistic infections and hospitalisations in adults 
with AIDS after 6 - 12 months of HAART intervention is well 
documented.[10] Decreases in hospitalisations and deaths result 
in a substantial reduction in the healthcare costs associated with 
infection. The Children with HIV Early Antiretroviral Therapy Trial 
showed that early diagnosis and early antiretroviral therapy (ART) 
reduced early infant mortality by 76% and HIV progression by 
75%.[11] Worldwide, very few studies on the impact of HAART on 
vertically infected children and adolescents have been done.[10]
The other major intervention to reduce pneumonia-related 
morbidity and mortality among all children is implementation of 
preventive strategies. Routine immunisations against Streptococcus 
pneumoniae, Haemophilus influenzae and varicella are safe and 
effective even in HIV-infected children, in whom the primary 
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immunological response is inferior and 
there is faster decay in immunological 
memory.[3] The role of nutritional inventions, 
such as exclusive breastfeeding and zinc 
supplements, in the prevention of pneumonia 
among HIV-infected children needs to be 
explored more thoroughly.[11,12]
Objective
The primary aim of this study was to assess 
the prevalence of bacterial LRTIs in HIV-
infected and uninfected children. The 
secondary aim was to assess the outcome of 
bacterial LRTIs in infected and uninfected 
children managed at a primary level hospital.
Methods
It was hypothesised that there is no difference 
in the rate of LRTIs in HIV-positive children 
on HAART compared with HIV-negative 
children.
A cross-sectional descriptive study of 
children aged 6 months - 18 years was 
conducted at Tshwane District Hospital 
(TDH), Pretoria, SA, from January 2014 to 
September 2014. Two cohorts of children 
were recruited: a group of HIV-infected chil-
dren who had been on HAART for at least 6 
months, and a comparator group consisting 
of HIV-negative children admitted to the 
inpatient paediatric ward with a diagnosis of 
bacterial pneumonia.
For both groups of children, data collected 
included demographic information, number 
of healthcare visits for LTRIs in the past, 
number of antibiotic courses given for 
LRTIs, immunisation status (confirmed 
by assessment of the Road to Health card 
(RTHC)), documented zinc supplementation 
on the RTHC, and finally exposure to 
biomass fuels and environmental tobacco 
smoke. For the HIV-positive group, data 
collected included an assessment of HIV 
stage, which included CD4+ T-cell counts, 
HIV viral load and duration of HAART. 
Patients were excluded if their HIV status 
was unknown or if consent could not be 
obtained for HIV testing.
Statistical analysis
Data analysis was performed using Stata 12 
(StataCorp LP, 2011; Statistical Software, 
USA). Summary statistics for all variables 
were done. Fisher’s exact test was used for 
assessing the association between categorical 
variables in the HIV-infected and uninfected 
children, and a two-sample independent 
t-test for proportions for comparisons of 
proportions of patients, both HIV-infected 
and uninfected, who had records of 
antibiotic therapy, zinc supplementation and 
immunisation. Similarly, a two-sample t-test 
was used for gender comparisons in the 
HIV-uninfected group. Testing was done at 
the 0.05 level of significance.
Results
A total of 59 HIV-infected children were 
recruited. Of 623 children screened for the 
HIV-uninfected group, only 20 met the 
inclusion criteria. The majority of children 
who were screened had either bronchiolitis 
or asthma.
The children in the HIV-uninfected group 
were younger (mean age 12.0 (standard 
deviation (SD) 5.8) months) than the HIV-
infected children (mean age 107.2 (50.0) 
months) (p<0.005).
The majority of the HIV-infected 
children had been diagnosed after the 
age of 2 years, with most having been on 
HAART for over 5 years and having immune 
restoration with normal CD4+ T-cell counts 
(Table 1). When all the demographic and 
clinical variables in the HIV-infected group 
of children were compared, there was no 
statistically significant difference in any 
of the variables when comparisons were 
performed according to gender (all p>0.05) 
(Fig. 1). None of the HIV-infected patients 
received oxygen therapy, as they were seen 
and managed at an outpatient department or 
local clinics, with only one child requiring 
admission. Thirty-one (52.5%) of these 
children received antibiotics for LRTIs; only 
one had complicated pneumonia. None of 
these HIV-infected children had a record 
of zinc supplementation. The majority of 
the HIV-infected group (66.7%) also did 
not have a complete immunisation record. 
Twelve (20.3%) of the HIV-infected children 
had had five visits to the TDH clinic for 
an LRTI, and 15.3% had had three visits. 
Amoxicillin was the antibiotic of choice 
in 98.3% of cases. One patient had only 
received erythromycin.
Of the HIV-uninfected children who were 
admitted with an LRTI and screened during 
the study period, only 3.2% had bacterial 
pneumonia. The gender distribution was 
Table 1. Demographic and clinical variables of the HIV-positive children (N=59)
Variable
Age (months), mean (95% CI) 107.2 (94.20 - 120.26)
Gender (M/F), n (%) 21/38
Age at diagnosis (months), mean (95% CI) 34.5 (24.33 - 44.71)
Duration of HAART (months), mean (95% CI) 66.0 (59.09 - 72.18)
CD4+ T-cell percentage, mean (95% CI) 31.5 (29.38- 33.71)
CD4+ T-cell (cells/µL), mean (95% CI) 1 032.9 (877.86 - 1 188.22)
HIV viral load (copies/mL), mean (95% CI) 47 884 (0.0 - 108 947.60)
Visits,* mean (95% CI) 3.9 (3.79 - 4.17)
CI = confidence interval; M = males; F = females.
*Number of visits for an LRTI since birth.
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Fig. 1. Demographic and laboratory parameters of HIV-infected children according to gender.
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unbalanced, with 60.0% males, and the average age of the children 
was 12 months (Table 2). There was no difference in mean age 
at admission when the males and females were compared (13.87 
months (95% confidence interval (CI) 9.62 - 18.12) v. 10.75 months 
(95% CI 6.84 - 14.66), respectively) (p=0.233). The most common 
presenting symptoms of pneumonia were cough, found in all children 
(100.0%), fast breathing (n=16, 80.0%) and chest indrawing (n=14, 
70.0%). More females than males presented with chest indrawing 
(n=6 (33.3%) v. n=5 (25.0%)), but this was not statistically significant 
(p=0.41). Of the children with pneumonia, five required oxygen 
therapy. The mean CRP level was 463.0 mg/L, with no significant 
difference in CRP levels between males and females (450.8 mg/L 
(95% CI 327.7 - 573.9) v. 481.2 mg/L (95% CI 158.1 - 804.3), 
respectively) (p=0.841). The average number of admission days 
was 4.4, with no difference in number of days when the males and 
females were compared (p=0.663). Intravenous ampicillin was the 
first-line antibiotic of choice, with only 12.5% receiving ampicillin 
and amikacin and only one patient initiated on second-line therapy 
(ceftriaxone) owing to failed first-line treatment. 
Exposure to biomass fuels was low in this study population (only 
7.0%), the majority of the children’s homes having electric stoves. No 
children were exposed to tobacco smoke. There was no record of zinc 
supplementation in any of the children’s RTHCs. Breastfeeding rates 
were high, with 95.0% of all children being breastfed. Overall, 85.0% 
of the children were fully immunised, the proportion being higher 
among males than females (91.7% v. 75.0%), although this did not 
reach statistical significance (p=0.085).
When the HIV-uninfected and HIV-infected groups were 
compared, all the HIV-uninfected children had been treated with 
antibiotics as opposed to 52.5% of the HIV-infected group (p<0.005). 
There was no documented record of zinc supplementation in 
either group. Immunisation rates differed between the groups, with 
more HIV-positive children than HIV-negative children having an 
incomplete record (62.0% v. 15.0%); this was statistically significant 
(p=0.002).
Discussion
This study shows that diagnosis of HIV infection and initiation of 
HAART may still be delayed in children; despite this, however, once 
HAART is initiated the burden of bacterial LTRIs is low, with children 
experiencing an average of less than one bacterial infection per year 
in the first 8 years of their lives. Admission rates for pneumonia were 
also very low, with no serious sequelae. Of concern are relatively 
low clinic attendance rates, with two-thirds of HIV-infected children 
having an incomplete immunisation record.
For the HIV-uninfected group, viral LRTIs were the most common 
cause for admission, with children who presented with bacterial 
LRTIs being younger than 2 years and typically having uncomplicated 
pneumonia with good outcomes. Cough and fast breathing remain 
the major presenting symptoms for bacterial pneumonia. Penicillin-
based antibiotics were the first-line therapy in most cases, with the 
average duration of treatment being less than 5 days. Immunisation 
and breastfeeding rates were high and biomass exposures low.
HAART improves survival in HIV-infected children. The majority 
of HIV-infected children in the current study had been on HAART 
for over 5 years and had a normal CD4+ T-cell count and a 
suppressed HIV viral load. This may account for the low levels 
of recorded bacterial LRTIs and low complication rates. Sánchez 
et al.[13] found that HAART results in a lower risk of death at 
5 years’ follow-up. The impact of ART on lung health of HIV-
infected persons is not well understood. Systemically, treatment with 
ART decreases HIV replication, immune activation and chronic 
inﬂammation and increases CD4+ T-lymphocyte counts. Within the 
alveolar space, ART decreases the pulmonary HIV viral load and 
decreases pulmonary inﬂammatory responses.[8] The present study 
confirms the effectiveness of HAART as the best intervention for the 
prevention of pneumonia, and consequently of hospitalisations and 
deaths, in children and adolescents living with HIV/AIDS. This is 
supported by the findings of Candiani et al.[10]
According to the WHO, pneumonia accounts for 19% of deaths of 
children aged under 5 and for 4% of neonatal deaths worldwide.[14] In 
SA, the mortality rate from pneumonia in children increased from 
21/1 000 to 103/1 000 between 2003 and 2009. The annual incidence 
of pneumonia in children younger than 5 years of age in SA remains 
high, and pneumonia is one of the major causes of mortality in this age 
group.[15] Determining the causation of bacterial pneumonia in children 
is difficult, as specimens for culture are difficult to obtain and often 
yield negative results. For this reason several studies have advocated the 
use of empirical treatment, since S. pneumoniae is the most common 
bacterial pathogen identified in children aged 4 weeks and older in 
developing countries. The role of S. pneumoniae in serious infections 
has decreased significantly since the introduction of the pneumococcal 
conjugate vaccine (PCV).[16,17] In SA the PCV7 vaccine was included in 
the immunisation schedule in the public sector (which caters for over 
80% of the population) in 2009.[18] In the current study, the majority of 
HIV-negative children were under 5 years of age and therefore fell into 
the group that would have benefited from this vaccine.
Vaccination with PCV is a public health intervention to prevent 
pneumococcal disease, and it was licensed in the USA for use in 
Table 2. Demographic and clinical characteristics of the HIV-
negative children with pneumonia (N=20)
Variable
Age (months), mean (95% CI) 12.0 (9.27 - 14.72)
Gender (M/F), n (%) 12/8 (60.0/40.0)
Cough, n (%) 20 (100.0)
Fast breathing, n (%) (95% CI) 16 (80.0) (0.55 - 0.93)
Chest indrawing, n (%) (95% CI) 14 (70.0) (0.45 - 0.87)
Admission (days), mean (95% CI) 4.4 (3.77 - 5.03)
CRP (mg/L), mean (95% CI) 463.0 (333.1 - 592.9)
Supplemental oxygen, n (%) (95% CI) 5 (25.0) (0.10 - 0.50)
Antibiotics, n (%) 20 (100.0) 
Breastfeeding, n (%) (95% CI) 19 (95.0) (0.67 - 0.99)
Immunisation, n (%) (95% CI) 17 (85.0) (0.59 - 0.95)
Zinc supplementation, n (%) 0 (0.0)
Table 3. Comparison of variables between HIV-uninfected and 
HIV-infected children presenting with pneumonia
Variable HIV-positive HIV-negative p-value
N 59 20
Gender (F/M), n 21/38 8/12 NS
Age (months), mean (SD) 12.0 (5.8) 107.0 (50.0) <0.005
Zinc supplementation, % 0 0 NS
Antibiotics, % 52 100 0.0001
Immunisation, % 33.3 85.0 0.0002
M = males; F = females; NS = not statistically significant.
RESEARCH
557       July 2015, Vol. 105, No. 7
children in 2000. This vaccine is suitable for use in infants and 
includes the most commonly identified serotypes, namely 4, 6B, 
9V, 14, 18C, 19F and 23F.[19] Recently two new vaccines covering 
other serotypes such as 1 and 5, which are highly invasive and 
responsible for severe illness and hospitalisation in young children, 
have been implemented, i.e. PCV10 and PCV13.[20] Several studies 
on the PCV vaccine have shown that it is effective in reducing 
invasive pneumococcal disease and hopitalisations.[21] We have 
observed that the majority of children admitted with ‘pneumonia’ 
and screened had viral bronchiolitis, with very few having bacterial 
pneumonia.
Most guidelines suggest treatment with amoxicillin as first-line 
antibiotic therapy for community-acquired bacterial pneumonia.[22] In 
our cohort, amoxicillin was the antibiotic of choice for both groups, 
while the first choice for inpatient therapy for the HIV-negative group 
was ampicillin. The response to treatment was good, based on the 
short length of hospital stay and the lack of significant complications 
observed, probably because S. pneumoniae remains the most common 
bacterial pathogen causing community-acquired pneumonia.
Healthy children are vulnerable to pneumonia when their immune 
system is weakened. Factors involved include parental smoking and 
indoor pollution, which is a huge problem in Africa, where about 
700 million people burn biomass fuels to provide energy to cook. 
Smith et al.[23] have demonstrated in a randomised controlled trial 
that biomass exposure is a significant risk factor for pneumonia. We 
found low levels of biomass exposure, which may explain the low 
levels of bacterial pneumonia found in our study.
Other preventive strategies to reduce pneumonia morbidity and 
mortality include the use of the IMCI programme. In SA, use of 
this programme at primary care level has been shown to be very 
effective for the diagnosis and management of pneumonia.[24] In 
the current study, cough and fast breathing were the most common 
presenting symptoms, as per the WHO definition of pneumonia, 
confirming the value of these clinical symptoms for the diagnosis of 
pneumonia at primary care level. Acute-phase reactants such as CRP 
have been extensively studied in the evaluation and prognostication 
of pneumonia. Various cut-points for diagnosis have been suggested, 
with values ranging between 300 and 560 mg/L.[25] Youssef et al.[26] 
demonstrated a correlation between a high CRP level (mean in 
their study 916.8 mg/L) and severity of pneumonia and the need for 
intensive care unit (ICU) admission. In the current study, the mean 
CRP level was 460 mg/L and none of the patients had a prolonged 
hospital stay or required ICU admission.
The value of zinc supplementation as an adjuvant therapy for 
pneumonia prevention is still not well established. Shah et al.[27] 
performed a randomised double-blind placebo-controlled study and 
concluded that there was no significant reduction in duration of 
hospital stay. The majority of children in the current study did not 
receive any zinc supplementation; this did not seem to impact upon 
the severity or number of LRTIs experienced by children in this 
cohort, although our numbers were small.
Study limitations
The limitations of this study were the small numbers of children, 
particularly in the HIV-uninfected group, as the majority of children 
admitted had a viral LRTI. The fact that the HIV-infected children 
were older makes it difficult to compare them with a younger HIV-
uninfected group, as younger children generally experience more 
LRTIs.
Recommendations
Future randomised controlled trials focusing on the role of zinc 
supplementation on the prevention of bacterial LRTIs in both HIV-
infected and uninfected children should be conducted. In the current 
study, the HIV-infected children were older and a follow-up study of the 
same cohort of children in 5 years’ time would be interesting to assess 
the ongoing protective role of HAART and its impact on lung health in 
adolescence.
Conclusion 
HAART is effective in reducing the burden of LRTIs in children, 
even when the diagnosis of HIV infection is delayed. Cough and fast 
breathing are the most reliable presenting symptoms for pneumonia. 
The majority of children respond to amoxicillin as first-line therapy.
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